

LIST OF FIGURES

Figures in Chapter 1

Figure 1.1.	Structures of 2,3-dihydrobenzofuran, chroman, 1,4-benzodioxane, and 1-benzoxepane skeletons.....	4
Figure 1.2.	Representative examples of biologically active chroman derivatives.....	6
Figure 1.3.	The most well-known strategies used for constructing the chroman ring.....	7
Figure 1.4.	Bent bonding in ethylene oxide (the parent epoxide).....	7
Figure 1.5.	Unsubstituted-, activated- and non-activated aziridines.....	9
Figure 1.6.	Vicinal diols.....	9

Figures in Chapter 2

Figure 2.1.	General structures of chroman-3-ol, flavon-3-ols, 4-arylflavan-3-ols, and 4-arylchroman -3-ols and representative examples of biologically important chroman-3-ols.....	30
Figure 2.2.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8a	90
Figure 2.3.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8a	90
Figure 2.4.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8g	91
Figure 2.5.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8g	91
Figure 2.6.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8s	92
Figure 2.7.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8s	92
Figure 2.8.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8w	93
Figure 2.9.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8w	93
Figure 2.10.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 30b	94
Figure 2.11.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 30b	94
Figure 2.12.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 31b	95
Figure 2.13.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 31b	95
Figure 2.14.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 33	96
Figure 2.15.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 33	96

Figures in Chapter 3

Figure 3.1.	Brazilin family of natural products.....	98
Figure 3.2.	Tetralinanalogs of brazilin and haematoxylin.....	98
Figure 3.3.	Lactone, lactam and tetrahydroquinolineanalogs of brazilin/brazilane.....	99
Figure 3.4.	Chroman-fused tetralins as B-ring-modified analogues of brazilin.....	99
Figure 3.5.	ORTEP diagram of 7k	105
Figure 3.6.	ORTEP diagram of 7k with 35% probability ellipsoid.....	127
Figure 3.7.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8a	131
Figure 3.8.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8a	132
Figure 3.9.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8b	133
Figure 3.10.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8b	134
Figure 3.11.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8c	135
Figure 3.12.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8c	136
Figure 3.13.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 8d	137
Figure 3.14.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 8d	138
Figure 3.15.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 7a	139
Figure 3.16.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 7a	140
Figure 3.17.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 7i	141
Figure 3.18.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 7i	142
Figure 3.19.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 7j	143
Figure 3.20.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 7j	144
Figure 3.21.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 7m	145
Figure 3.22.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 7m	146
Figure 3.23.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 16	147
Figure 3.24.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 16	148

Figures in Chapter 4

Figure 4.1.	Antihypertensive drug nebivolol and its biologically active stereoisomers.....	150
Figure 4.2.	Late-stage intermediates for the asymmetric synthesis of	154

	(<i>S,R,R,R</i>)-neбиволол 1a	
Figure 4.3.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 42	177
Figure 4.4.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 42	177
Figure 4.5.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound (<i>2R,3S</i>)- 43	178
Figure 4.6.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound (<i>2R,3S</i>)- 43	178
Figure 4.7.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound (<i>R,S</i>)- 47 ...	179
Figure 4.8.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound (<i>R,S</i>)- 47 ..	179
Figure 4.9.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound (<i>R,R</i>)- 25 ..	180
Figure 4.10.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound (<i>S,R</i>)- 28 ..	180
Figure 4.11.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound (<i>S,R</i>)- 29 ..	181
Figure 4.12.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound (<i>S,R</i>)- 29 ..	181

Figures in Chapter 5

Figure 5.1.	Representative examples of biologically important β-amino alcohols.....	183
Figure 5.2.	Representative examples of biologically important β-amino alcohols.....	185
Figure 5.3.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 12a	206
Figure 5.4.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 12a	206
Figure 5.5.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 12b	207
Figure 5.6.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 12b	207
Figure 5.7.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 15a	208
Figure 5.8.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 15a	208
Figure 5.9.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 15b	209
Figure 5.10.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 15b	209
Figure 5.11.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 5a	210
Figure 5.12.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 5a	210
Figure 5.13.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 5b	211
Figure 5.14.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 5b	211
Figure 5.15.	HPLC chromatogram of 12a	212

Figure 5.16.	HPLC chromatogram of 12b	212
--------------	---------------------------------------	-----

Figures in Chapter 6

Figure 6.1.	¹ H NMR (400 MHz, CDCl ₃) and ¹³ C NMR (100 MHz, CDCl ₃) spectra (partial) of 13a	220
Figure 6.2.	ORTEP of compound 13e with 35% probability ellipsoid (only one asymmetric molecule is displayed for clarity).....	221
Figure 6.3.	Structure confirmation of 15 by ¹ H NMR.....	223
Figure 6.4.	Hydrogen bonding in the solid-state structure of 13e	252
Figure 6.5.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 12c	256
Figure 6.6.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 12c	256
Figure 6.7.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 12e	257
Figure 6.8.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 12e	257
Figure 6.9.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 12h	258
Figure 6.10.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 12h	258
Figure 6.11.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 13c	259
Figure 6.12.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 13c	259
Figure 6.13.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 13g	260
Figure 6.14.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 13g	260
Figure 6.15.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 13h	261
Figure 6.16.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 13h	261
Figure 6.17.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 15	262
Figure 6.18.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 15	262
Figure 6.19.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 23	263
Figure 6.20.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 23	263
Figure 6.21.	¹ H NMR (400 MHz, CDCl ₃) spectrum of compound 25	264
Figure 6.22.	¹³ C NMR (100 MHz, CDCl ₃) spectrum of compound 25	264

Figures in Chapter 7

Figure 7.1.	Benzimidazole and 2-arylbenzimidazoles.....	266
Figure 7.2.	1,4-Benzoxazepine scaffold.....	266
Figure 7.3.	The chemical structures of the designed target compounds.....	267
Figure 7.4.	2-Aryloxiranes 7g and 7h	270

Figure 7.5.	^1H NMR (400 MHz, CDCl_3) spectrum of compound 1b	293
Figure 7.6.	^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 1b	293
Figure 7.7.	^1H NMR (400 MHz, CDCl_3) spectrum of compound 1c	294
Figure 7.8.	^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 1c	294
Figure 7.9.	^1H NMR (400 MHz, CDCl_3) spectrum of compound 1f	295
Figure 7.10.	^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 1f	295
Figure 7.11.	^1H NMR (400 MHz, CDCl_3) spectrum of compound 1h	296
Figure 7.12.	^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 1h	296
Figure 7.13.	^1H NMR (400 MHz, CDCl_3) spectrum of compound 23	297
Figure 7.14.	^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 23	297
Figure 7.15.	^1H NMR (400 MHz, CDCl_3) spectrum of compound 24	298
Figure 7.16.	^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 24	298